Merck
NYSE: MRK · Health Care · Pharmaceuticals · RAHWAY, NJ
Pharmaceutical company led by cancer immunotherapy Keytruda and the Gardasil HPV vaccine, with a separate Animal Health segment.
Annual results
Click any number to open the SEC filing it came from.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $48.7B | $59.3B | $60.1B | $64.2B | $65.0B |
| Net income | $13.0B | $14.5B | $365.0M | $17.1B | $18.3B |
| EPS — diluted | $5.14 per share | $5.71 per share | $0.14 per share | $6.74 per share | $7.28 per share |
| Cash from operations | — | $19.1B | $13.0B | $21.5B | $16.5B |
| Free cash flow | — | $14.7B | $9.1B | $18.1B | $12.4B |
| Total assets | $105.7B | $109.2B | $106.7B | $117.1B | $136.9B |
Recent filings
Members see much more
The full MRK file, with an AI analyst on it.
- Quarterly statements, segments and IR data
- Valuation, earnings and insider activity
- A research assistant that cites the filing sentence